Evotec Forschung services by Evotec SE - tailored discovery partnerships

Evotec Forschung services sit behind lab doors where pipettes click, incubators hum and fluorescent assay plates glow under blue light. These discovery programs turn partners’ ideas into drug candidates using Evotec’s platforms, and Chief Scientific Officer Dr Werner Lanthaler pushes the teams to keep data tight and timelines clear.

From hit to lead with partners

Evotec Forschung bundles several discovery offerings for partners, from hit identification campaigns to lead optimization programs in small molecules and biologics. Inside the hit identification modules, partners tap curated compound libraries, screening platforms and fragment-based approaches tailored to the therapeutic target.

These services are not off-the-shelf kits; they are structured collaboration packages with defined work packages, data delivery points and IP sharing frameworks that pharma or biotech clients negotiate with Evotec. A typical partner might bring a target hypothesis and rely on Evotec for assay development, screening, medicinal chemistry and early DMPK profiling.

Platform backbone for Evotec Forschung

Under the Evotec Forschung umbrella, partners access platforms such as EVOscreen for high-throughput screening, PanOmics for multi-omics profiling and INDiGO for integrated IND-enabling studies. Each platform carries its own validated workflows, data standards and reporting formats that plug into partner pipelines.

In practice, an oncology biotech might combine PanOmics transcriptomics with EVOscreen and medicinal chemistry to shape a first-in-class small molecule program. Evotec describes these offerings as modular, allowing partners to start with one work package and scale to full discovery alliances spanning several years.

How partners use the service

On the Evotec Forschung pages for drug discovery alliances, Evotec outlines three core collaboration formats: fee-for-service projects, integrated drug discovery alliances and co-owned programs with shared risk and shared IP. Smaller biotechs often start with fee-for-service assay development before moving into integrated alliances once a hit series emerges.

Larger pharma partners, including names like Bristol Myers Squibb and Bayer in separate publicized deals, have used Evotec’s discovery services to expand early portfolios in areas such as immunology and neuroscience. In these alliances, Evotec’s scientists run lab work while joint steering committees set priorities, milestones and go/no-go decisions.

Pricing and availability

Evotec does not list standard prices for Evotec Forschung services publicly; instead, budgets are scoped per project based on duration, platform mix and IP structure, typically negotiated in euros with European partners or US dollars with North American clients. Projects can run from a few months for focused screening up to multi-year alliances.

Availability is centered on Evotec’s research sites in Hamburg, Toulouse, Verona, Abingdon, and several other locations where the company operates discovery labs and screening centers. Partners usually sign Master Service Agreements or broader collaboration contracts, then open individual work orders for defined programs.

Management stance on discovery services

CEO Dr Werner Lanthaler has repeatedly framed Evotec’s discovery services, including Evotec Forschung, as the engine that feeds the company’s co-owned pipeline and long-term milestone streams. In investor presentations, he highlights that integrated alliances create more value than pure fee-for-service work because Evotec keeps a slice of future upside.

Head of Global Business Development Dr Craig Johnstone has also outlined how Evotec’s discovery offerings target small and mid-sized biotechs that lack in-house screening or medicinal chemistry capacity. For these clients, Evotec Forschung acts almost like a virtual discovery department anchored in Evotec’s labs.

Implications for investors and the share

For retail investors watching Evotec, the Evotec Forschung service line matters because it supports recurring service revenues and seeds future milestone and royalty income from partnered programs. Discovery alliances signed today might generate clinical-stage assets several years later, with corresponding financial triggers tied to progress.

On Xetra in Frankfurt, the Evotec SE share trades as a mid-cap biotech/services stock where news about new discovery alliances and platform extensions can influence sentiment. Evotec SE stock is listed on Xetra in euros under ISIN DE0005664809.